AI Engines For more Details: Perplexity Kagi Labs You
Pancreatitis: Gabexate mesilate has been investigated as a treatment for acute pancreatitis. Studies have suggested that it may help reduce inflammation and tissue damage in the pancreas by inhibiting the activation of pancreatic enzymes and the release of inflammatory mediators. However, its effectiveness in improving clinical outcomes in pancreatitis remains a subject of debate, and further research is needed.
Liver Disease: Gabexate mesilate has been studied for its potential hepatoprotective effects in liver diseases such as hepatitis and liver cirrhosis. It may help reduce liver inflammation and fibrosis by inhibiting the activity of proteases involved in tissue damage. However, more clinical trials are needed to determine its efficacy and safety in the management of liver disorders.
Sepsis: Some studies have suggested that gabexate mesilate may have anti-inflammatory and immunomodulatory effects that could be beneficial in the treatment of sepsis, a life-threatening condition characterized by systemic inflammation and organ dysfunction. It may help mitigate the inflammatory response and prevent organ damage in septic patients, but further research is required to confirm its efficacy in clinical settings.
Surgical Complications: Gabexate mesilate has been investigated for its potential to reduce postoperative complications in patients undergoing surgery, particularly gastrointestinal surgery. By inhibiting proteases involved in tissue injury and inflammation, it may help improve wound healing and reduce the risk of complications such as infection and organ dysfunction. However, its role in surgical practice remains to be established through more rigorous clinical studies.
Other Conditions: Gabexate mesilate has also been explored for its potential therapeutic effects in conditions such as acute respiratory distress syndrome (ARDS), acute lung injury, and acute myocardial infarction. However, the evidence regarding its efficacy in these conditions is limited and inconclusive.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 3.3 | 0.1 | 32 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | |
Allergic Rhinitis (Hay Fever) | 0.7 | 1.7 | -1.43 |
Allergies | 3.4 | 1.5 | 1.27 |
Allergy to milk products | 0.7 | 0.5 | 0.4 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 2.2 | 3.3 | -0.5 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.9 | 1.11 |
Ankylosing spondylitis | 2.5 | 0.5 | 4 |
Anorexia Nervosa | 1.1 | -1.1 | |
Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
Asthma | 0.8 | 1.3 | -0.63 |
Atherosclerosis | 0.9 | 1.6 | -0.78 |
Atrial fibrillation | 1.9 | 0.7 | 1.71 |
Autism | 5.8 | 4.9 | 0.18 |
Barrett esophagus cancer | 0.6 | 0.3 | 1 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.3 | 0.8 | -1.67 |
Brain Trauma | 0.7 | 0.4 | 0.75 |
Carcinoma | 2.3 | 1.7 | 0.35 |
Celiac Disease | 1.5 | 2.6 | -0.73 |
Cerebral Palsy | 1.6 | 0.7 | 1.29 |
Chronic Fatigue Syndrome | 2.9 | 3.2 | -0.1 |
Chronic Kidney Disease | 1.3 | 0.8 | 0.63 |
Chronic Lyme | 0.4 | -0.4 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 0.3 | 6.33 |
Chronic Urticaria (Hives) | 1.5 | 0.6 | 1.5 |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.9 | -0.13 |
Colorectal Cancer | 3 | 0.8 | 2.75 |
Constipation | 0.4 | 0.6 | -0.5 |
Coronary artery disease | 0.6 | 0.7 | -0.17 |
COVID-19 | 8.3 | 8.5 | -0.02 |
Crohn's Disease | 4.6 | 2.7 | 0.7 |
cystic fibrosis | 0.5 | 0.8 | -0.6 |
deep vein thrombosis | 0.5 | 0.6 | -0.2 |
Depression | 5.7 | 5 | 0.14 |
Dermatomyositis | 0.3 | 0.3 | 0 |
Eczema | 0.7 | 1.7 | -1.43 |
Endometriosis | 1.9 | 0.6 | 2.17 |
Eosinophilic Esophagitis | 0.2 | 0.4 | -1 |
Epilepsy | 2.2 | 1.6 | 0.38 |
Fibromyalgia | 1.5 | 1.1 | 0.36 |
Functional constipation / chronic idiopathic constipation | 2.7 | 1.9 | 0.42 |
gallstone disease (gsd) | 1.4 | 0.8 | 0.75 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.9 | -0.29 |
Generalized anxiety disorder | 1.1 | 1.4 | -0.27 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Graves' disease | 0.9 | 1.3 | -0.44 |
Halitosis | 0.8 | 0.3 | 1.67 |
Hashimoto's thyroiditis | 2.3 | 0.5 | 3.6 |
Hidradenitis Suppurativa | 0.5 | 0.4 | 0.25 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | 0.6 | 2.67 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
hyperglycemia | 0.2 | 1.6 | -7 |
Hyperlipidemia (High Blood Fats) | 1 | 0.4 | 1.5 |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.7 | 3.6 | -1.12 |
Hypothyroidism | 0.8 | -0.8 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1.7 | -1.7 | |
Inflammatory Bowel Disease | 3.1 | 4.1 | -0.32 |
Insomnia | 0.8 | 0.5 | 0.6 |
Intelligence | 0.6 | 0.6 | |
Intracranial aneurysms | 0.5 | 0.4 | 0.25 |
Irritable Bowel Syndrome | 2.9 | 2.6 | 0.12 |
Liver Cirrhosis | 3.2 | 2.3 | 0.39 |
Long COVID | 4 | 5.2 | -0.3 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.4 | 1.1 | -1.75 |
ME/CFS with IBS | 0.6 | 1.7 | -1.83 |
ME/CFS without IBS | 1.2 | 1.4 | -0.17 |
Menopause | 1.8 | 1.8 | |
Metabolic Syndrome | 4.8 | 5.9 | -0.23 |
Mood Disorders | 7.9 | 5.2 | 0.52 |
multiple chemical sensitivity [MCS] | 1.8 | 0.3 | 5 |
Multiple Sclerosis | 4.6 | 1.7 | 1.71 |
Multiple system atrophy (MSA) | 2 | 0.6 | 2.33 |
Neuropathy (all types) | 0.9 | 0.2 | 3.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 3.7 | -1.18 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 6.4 | 3.6 | 0.78 |
obsessive-compulsive disorder | 3.1 | 2.7 | 0.15 |
Osteoarthritis | 1.4 | 1.4 | |
Osteoporosis | 1.1 | 1 | 0.1 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 2.3 | 2.1 | 0.1 |
Polycystic ovary syndrome | 0.9 | 1.3 | -0.44 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 1 | 1 | |
primary biliary cholangitis | 0.3 | 0.7 | -1.33 |
Psoriasis | 3.6 | 1 | 2.6 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 2.5 | 0.6 |
Rosacea | 1 | 0.5 | 1 |
Schizophrenia | 5 | 1.1 | 3.55 |
scoliosis | 0 | 0 | |
Sjögren syndrome | 2.2 | 2.3 | -0.05 |
Sleep Apnea | 0.8 | 0.9 | -0.13 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.6 | 0.5 |
Stress / posttraumatic stress disorder | 2.2 | 2 | 0.1 |
Systemic Lupus Erythematosus | 2 | 1.1 | 0.82 |
Tic Disorder | 0.3 | 1 | -2.33 |
Tourette syndrome | 0.3 | 0.2 | 0.5 |
Type 1 Diabetes | 1.5 | 1.6 | -0.07 |
Type 2 Diabetes | 4.7 | 4.1 | 0.15 |
Ulcerative colitis | 2.2 | 2.9 | -0.32 |
Unhealthy Ageing | 2.8 | 1.3 | 1.15 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.